US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% INTC $113.12 ▲+0.55%
FinancialContent

Articles published by Lexicon Pharmaceuticals, Inc.

News headline image
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers HTGC LXRX
News headline image
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Announces Proposed Public Offering of Common Stock
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
News headline image
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX